首页> 外文期刊>BJU international >The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
【24h】

The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.

机译:前列腺癌根治术后病理Gleason评分≥8的患者的结局。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To analyse the outcome of patients undergoing radical prostatectomy (RP) for Gleason 8-10 clinically localized prostate cancer, and to evaluate the prognostic value of well-known predictors of progression. PATIENTS AND METHODS: In all, 1480 patients had RP between 1988 and 2006, of whom 180 had pathological Gleason score >or=8 and negative lymph nodes. Biochemical progression-free survival was determined using the Kaplan-Meier method. The effect of preoperative prostate-specific antigen (PSA) level, pathological stage and margin status was assessed with univariate and multivariate analyses. RESULTS: Of the 180 patients, the Gleason score in the RP specimen was 8, 9 or 10 in 70%, 27% and 3%, respectively; 24% had stage pT2 disease, 30% stage pT3a, 25% stage pT3b and 20% stage pT4a. The 5- and 7-year biochemical progression-free survival was 73 and 65% for stage pT2, 40% and 27% for stage pT3a, and 30% for stage pT3b (log rank test, P < 0.001). In the univariate model, preoperative PSA level, pathological stage and surgical margins were predictors of survival. In the multivariate analysis, preoperative PSA level and extracapsular extension predicted biochemical progression-free survival. CONCLUSION: Gleason 8-10 tumours have a poor prognosis. Patients with a PSA level of <10 ng/mL and stage pT2 disease have the greatest likelihood of having a longer progression-free survival after RP.
机译:目的:分析接受Gleason 8-10临床局限性前列腺癌的根治性前列腺切除术(RP)患者的预后,并评估众所周知的进展预测指标的预后价值。患者与方法:1988年至2006年间,共有1480例RP,其中180例病理性Gleason评分≥8且淋巴结阴性。使用Kaplan-Meier方法确定无生化进展的存活率。用单变量和多变量分析评估术前前列腺特异性抗原(PSA)水平,病理分期和切缘状态的影响。结果:180例患者中,RP标本的格里森评分分别为70%,27%和3%,分别为8、9或10。 24%患有pT2期疾病,30%患有pT3a期,25%患有pT3b期,20%患有pT4a期。 pT2期的5年和7年无生化无进展生存期分别为73%和65%,pT3a期为40%和27%,pT3b期为30%(对数秩检验,P <0.001)。在单变量模型中,术前PSA水平,病理分期和手术切缘是生存率的预测指标。在多变量分析中,术前PSA水平和囊外扩张可预测无生化进展的生存期。结论:格里森8-10肿瘤预后不良。 PSA水平<10 ng / mL且患有pT2期疾病的患者在RP后具有更长的无进展生存期的可能性最大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号